Skip to main navigation
Skip to search
Skip to main content
China Europe International Business School Home
English
中文
Home
Profiles
Communities & Collections
Research Output
Newspaper Articles and Columns
Search by expertise, name or affiliation
Opdivo: The Hard Way to Birth (B)
Eric Bouteiller
, Luis Liu, Wu Pei
Marketing
Case Development Centre
China Pharmaceutical University
Research output
:
Other contribution
›
Case Studies
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Opdivo: The Hard Way to Birth (B)'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Nivolumab
100%
Childbirth
100%
Ipilimumab
66%
Anticarcinogen
16%
Cytotoxic T Lymphocyte Antigen 4 Antibody
16%
Oncology
16%
Biopharmaceuticals
16%
CTLA-4
16%
6 Diazo 5 Oxonorleucine
16%
Cancer Immunotherapy
16%
Clinical Trial
16%
Immunoglobulin
16%
T Cell
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nivolumab
100%
Ipilimumab
66%
Pear
33%
Anticarcinogen
16%
Immunoglobulin
16%
Immunotherapy
16%
Clinical Trial
16%
6 Diazo 5 Oxonorleucine
16%
Cytotoxic T Lymphocyte Antigen 4 Antibody
16%
Cytotoxic T Lymphocyte Antigen 4
16%
Mouse
16%
Neoplasm
16%